CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
This innovative product eliminates two manufacturing steps and simplifies equipment setup
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Subscribe To Our Newsletter & Stay Updated